Interferon-α(2b) therapy is efficacious in Asian-Americans with chronic hepatitis B infection: A prospective controlled trial

Paul Martin, Hie Won Hann, Sharon Westerberg, Santiago J. Muñoz, Raphael Rubin, Willis C. Maddrey

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Chronic hepatitis B virus infection is endemic in Asian communities in the United States. The purpose of the current study was to compare the antiviral efficacy of interferon-α(2b) in a group of adult Asian patients chronically infected with hepatitis B with active replication compared to a control group of Caucasian patients treated with the same regimen. Patients with entry aminotransferase (ALT) levels greater than three times the upper limit of normal received interferon-α(2b), 5 million units, subcutaneously daily for 16 weeks. Patients with pretreatment ALT levels 1.5-3 times the upper limit of normal received prednisone for a total of six weeks prior to interferon starting at 60 mg daily with reduction in dosage by 20 mg every two weeks with a two-week period between finishing prednisone and starting interferon-α(2b). Eight (62%) of the 13 Asians and six (60%) of the 10 Caucasians cleared HBeAg and HBV DNA from serum (NS). By the end of one year of follow-up after therapy, four (67%) of six Caucasian responders but none of the Asian responders had cleared hepatitis B surface antigen from serum (P < 0.05). Loss of serum markers of active replication appeared less durable in the Asian responders compared to the Caucasians with reappearance of serum HBeAg in two (25%) of eight of the former but only one (17%) of the latter group. Three other Asian patients subsequently redeveloped HBeAg in serum. It is concluded that adult Asian-Americans have an identical initial response rate to antiviral therapy with interferon-α(2b); however, the response may be less durable and does not usually lead to loss of HBsAg.

Original languageEnglish
Pages (from-to)875-879
Number of pages5
JournalDigestive Diseases and Sciences
Volume43
Issue number4
DOIs
StatePublished - Apr 29 1998
Externally publishedYes

Fingerprint

Asian Americans
Chronic Hepatitis B
Interferons
Hepatitis B e Antigens
Infection
Hepatitis B Surface Antigens
Prednisone
Serum
Antiviral Agents
Therapeutics
Virus Diseases
Transaminases
Hepatitis B
Hepatitis B virus
Biomarkers
Control Groups
DNA

Keywords

  • Asians
  • Chronic hepatitis B
  • Interferon
  • Prednisone

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Interferon-α(2b) therapy is efficacious in Asian-Americans with chronic hepatitis B infection : A prospective controlled trial. / Martin, Paul; Hann, Hie Won; Westerberg, Sharon; Muñoz, Santiago J.; Rubin, Raphael; Maddrey, Willis C.

In: Digestive Diseases and Sciences, Vol. 43, No. 4, 29.04.1998, p. 875-879.

Research output: Contribution to journalArticle

Martin, Paul ; Hann, Hie Won ; Westerberg, Sharon ; Muñoz, Santiago J. ; Rubin, Raphael ; Maddrey, Willis C. / Interferon-α(2b) therapy is efficacious in Asian-Americans with chronic hepatitis B infection : A prospective controlled trial. In: Digestive Diseases and Sciences. 1998 ; Vol. 43, No. 4. pp. 875-879.
@article{2fadeb6bd0f14f9289d1a2a145345b9a,
title = "Interferon-α(2b) therapy is efficacious in Asian-Americans with chronic hepatitis B infection: A prospective controlled trial",
abstract = "Chronic hepatitis B virus infection is endemic in Asian communities in the United States. The purpose of the current study was to compare the antiviral efficacy of interferon-α(2b) in a group of adult Asian patients chronically infected with hepatitis B with active replication compared to a control group of Caucasian patients treated with the same regimen. Patients with entry aminotransferase (ALT) levels greater than three times the upper limit of normal received interferon-α(2b), 5 million units, subcutaneously daily for 16 weeks. Patients with pretreatment ALT levels 1.5-3 times the upper limit of normal received prednisone for a total of six weeks prior to interferon starting at 60 mg daily with reduction in dosage by 20 mg every two weeks with a two-week period between finishing prednisone and starting interferon-α(2b). Eight (62{\%}) of the 13 Asians and six (60{\%}) of the 10 Caucasians cleared HBeAg and HBV DNA from serum (NS). By the end of one year of follow-up after therapy, four (67{\%}) of six Caucasian responders but none of the Asian responders had cleared hepatitis B surface antigen from serum (P < 0.05). Loss of serum markers of active replication appeared less durable in the Asian responders compared to the Caucasians with reappearance of serum HBeAg in two (25{\%}) of eight of the former but only one (17{\%}) of the latter group. Three other Asian patients subsequently redeveloped HBeAg in serum. It is concluded that adult Asian-Americans have an identical initial response rate to antiviral therapy with interferon-α(2b); however, the response may be less durable and does not usually lead to loss of HBsAg.",
keywords = "Asians, Chronic hepatitis B, Interferon, Prednisone",
author = "Paul Martin and Hann, {Hie Won} and Sharon Westerberg and Mu{\~n}oz, {Santiago J.} and Raphael Rubin and Maddrey, {Willis C.}",
year = "1998",
month = "4",
day = "29",
doi = "10.1023/A:1018894804569",
language = "English",
volume = "43",
pages = "875--879",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Plenum Publishers",
number = "4",

}

TY - JOUR

T1 - Interferon-α(2b) therapy is efficacious in Asian-Americans with chronic hepatitis B infection

T2 - A prospective controlled trial

AU - Martin, Paul

AU - Hann, Hie Won

AU - Westerberg, Sharon

AU - Muñoz, Santiago J.

AU - Rubin, Raphael

AU - Maddrey, Willis C.

PY - 1998/4/29

Y1 - 1998/4/29

N2 - Chronic hepatitis B virus infection is endemic in Asian communities in the United States. The purpose of the current study was to compare the antiviral efficacy of interferon-α(2b) in a group of adult Asian patients chronically infected with hepatitis B with active replication compared to a control group of Caucasian patients treated with the same regimen. Patients with entry aminotransferase (ALT) levels greater than three times the upper limit of normal received interferon-α(2b), 5 million units, subcutaneously daily for 16 weeks. Patients with pretreatment ALT levels 1.5-3 times the upper limit of normal received prednisone for a total of six weeks prior to interferon starting at 60 mg daily with reduction in dosage by 20 mg every two weeks with a two-week period between finishing prednisone and starting interferon-α(2b). Eight (62%) of the 13 Asians and six (60%) of the 10 Caucasians cleared HBeAg and HBV DNA from serum (NS). By the end of one year of follow-up after therapy, four (67%) of six Caucasian responders but none of the Asian responders had cleared hepatitis B surface antigen from serum (P < 0.05). Loss of serum markers of active replication appeared less durable in the Asian responders compared to the Caucasians with reappearance of serum HBeAg in two (25%) of eight of the former but only one (17%) of the latter group. Three other Asian patients subsequently redeveloped HBeAg in serum. It is concluded that adult Asian-Americans have an identical initial response rate to antiviral therapy with interferon-α(2b); however, the response may be less durable and does not usually lead to loss of HBsAg.

AB - Chronic hepatitis B virus infection is endemic in Asian communities in the United States. The purpose of the current study was to compare the antiviral efficacy of interferon-α(2b) in a group of adult Asian patients chronically infected with hepatitis B with active replication compared to a control group of Caucasian patients treated with the same regimen. Patients with entry aminotransferase (ALT) levels greater than three times the upper limit of normal received interferon-α(2b), 5 million units, subcutaneously daily for 16 weeks. Patients with pretreatment ALT levels 1.5-3 times the upper limit of normal received prednisone for a total of six weeks prior to interferon starting at 60 mg daily with reduction in dosage by 20 mg every two weeks with a two-week period between finishing prednisone and starting interferon-α(2b). Eight (62%) of the 13 Asians and six (60%) of the 10 Caucasians cleared HBeAg and HBV DNA from serum (NS). By the end of one year of follow-up after therapy, four (67%) of six Caucasian responders but none of the Asian responders had cleared hepatitis B surface antigen from serum (P < 0.05). Loss of serum markers of active replication appeared less durable in the Asian responders compared to the Caucasians with reappearance of serum HBeAg in two (25%) of eight of the former but only one (17%) of the latter group. Three other Asian patients subsequently redeveloped HBeAg in serum. It is concluded that adult Asian-Americans have an identical initial response rate to antiviral therapy with interferon-α(2b); however, the response may be less durable and does not usually lead to loss of HBsAg.

KW - Asians

KW - Chronic hepatitis B

KW - Interferon

KW - Prednisone

UR - http://www.scopus.com/inward/record.url?scp=0031596619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031596619&partnerID=8YFLogxK

U2 - 10.1023/A:1018894804569

DO - 10.1023/A:1018894804569

M3 - Article

C2 - 9580255

AN - SCOPUS:0031596619

VL - 43

SP - 875

EP - 879

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 4

ER -